PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
70.32
ESG score exceeding 1.2x Biotechnology median of 58.08. Joel Greenblatt would verify if this ESG leadership translates to competitive advantages and pricing power.
70.45
Environmental score exceeding 1.2x Biotechnology median of 56.00. Joel Greenblatt would verify if this climate leadership creates pricing power and regulatory advantages.
73.76
Social score exceeding 1.2x Biotechnology median of 58.94. Joel Greenblatt would verify if this social leadership translates to employee productivity and customer loyalty advantages.
66.74
Governance score 1.1-1.2x Biotechnology median of 60.53. Philip Fisher would examine if superior governance practices support long-term value creation.